homepage-top-section

Pfizer and its partner BioNTech have submitted the initial data of an early-stage trial to the US Food and Drug Administration (FDA) to support the authorisation of a

Merck, called MSD outside the US and Canada, has initiated a rolling submission to Health Canada for molnupiravir, an investigational oral antiviral therapy for the treatment of Covid-19.

The US Food and Drug Administration (FDA) has authorised additional doses of Pfizer-BioNTech and Moderna Covid-19 vaccines for certain people with compromised immune systems. The regulatory agency has

The US Food and Drug Administration (FDA) has declined to approve AstraZeneca and FibroGen’s new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease

Biotechnology firm Moderna and Canadian government have signed a memorandum of understanding (MoU) to construct a new messenger RNA (mRNA) vaccine manufacturing facility in Canada. The latest deal

INO-4800 features a particularly designed deoxyribonucleic acid (DNA) plasmid. To be injected intradermally with subsequent electroporation, INO-4800 carries the DNA plasmid directly into body cells. Inovio’s partner, Advaccine

BRII-196 and BRII-198 are non-competing monoclonal antibodies obtained from convalesced Covid-19 patients. These antibodies neutralise SARS-CoV-2. The trial is funded by the NIH unit National Institute of Allergy

The European Commission has finalised an advanced purchase agreement (APA) with Novavax to buy up to 200 million doses of NVX-CoV2373, the company’s Covid-19 vaccine candidate. NVX-CoV2373 is

Sanofi has agreed to acquire a mRNA therapeutics firm Translate Bio to advance the use of messenger RNA (mRNA) technology across vaccines and therapeutics development. Under terms of